Wire · opportunities
MoonLake's nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
MoonLake Immunotherapeutics announced positive phase 3 trial results for its nanobody drug sonelokimab in treating psoriatic arthritis, meeting all primary and secondary clinical endpoints at 16 weeks in biologic-naïve patients. The drug is unique as a nanobody targeting interleukin 17F and 17A, and the trial will continue with comparison to existing treatments in a subsequent study.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should watch MoonLake's nanobody closely as it could open doors to new treatment options in a crowded psoriasis market with distinct drug targeting. Exclusivity on this nano-scale modality may create unique clinical advantages worth leveraging soon.
◆ Coverage
1 source · 10 Aug 2026
◆ Related on Wire
◆ Topics